LOS ANGELES, CA - May 28, 2026 (NEWMEDIAWIRE) - Regentis Biomaterials (NYSE American: RGNT) is taking aim at a $3 billion U.S. market with what could be the first true off-the-shelf solution for knee cartilage repair - no cells, no delays, no complexity. Its GelrinC(R) platform delivers faster recovery, stronger outcomes, and lower costs vs. outdated procedures, with clinical data showing approximately 100% greater pain improvement vs. microfracture. Already CE Mark approved in Europe and advancing through a pivotal U.S. Phase III trial, Regentis is stacked with near-term catalysts that could redefine orthopedic care - and unlock massive upside.

• GelrinC(R) is positioned as a potential first-in-class, off-the-shelf solution for knee cartilage repair in the U.S., offering a single-step procedure that simplifies treatment and integrates into standard surgical workflows.
• Clinical data show approximately 100% greater pain improvement versus microfracture, with durable outcomes and MRI-confirmed regeneration of near-native cartilage.
• A single approximately 10-minute procedure with approximately 2-week recovery and lower costs versus cell-based therapies supports strong adoption across surgeons, payers, and patients.
• The product targets an estimated approximately $3 billion U.S. market with approximately 470,000 annual cases and no comparable ready-to-use competitor.
• Advancing through a pivotal Phase III trial with CE Mark approval in Europe, the company is approaching key catalysts including commercialization and FDA submission.

Company Overview

Regentis is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on knee injuries and other orthopedic treatments, Regentis’ Gelrin(TM) platform technology, based on synchronized, degradable…

Read More

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward Looking Statements

Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law

This contant was orignally distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Regentis Biomaterials (RGNT) Is 'One to Watch'.